232 related articles for article (PubMed ID: 34197574)
1. Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis B Virus-Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort.
Dezanet LNC; Kassime R; Miailhes P; Lascoux-Combe C; Chas J; Maylin S; Gabassi A; Rougier H; Delaugerre C; Lacombe K; Boyd A
Clin Infect Dis; 2022 Mar; 74(6):1012-1021. PubMed ID: 34197574
[TBL] [Abstract][Full Text] [Related]
2. Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication.
Kouamé GM; Boyd A; Moh R; Badje A; Gabillard D; Ouattara E; Ntakpe JB; Emième A; Maylin S; Chekaraou MA; Eholié SP; Zoulim F; Lacombe K; Anglaret X; Danel C;
Clin Infect Dis; 2018 Jan; 66(1):112-120. PubMed ID: 29020361
[TBL] [Abstract][Full Text] [Related]
3. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.
Dezanet LNC; Miailhes P; Lascoux-Combe C; Chas J; Maylin S; Gabassi A; Rougier H; Delaugerre C; Lacombe K; Boyd A
Liver Int; 2021 Dec; 41(12):2874-2884. PubMed ID: 34297463
[TBL] [Abstract][Full Text] [Related]
4. Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.
Stockdale AJ; Phillips RO; Beloukas A; Appiah LT; Chadwick D; Bhagani S; Bonnett L; Sarfo FS; Dusheiko G; Geretti AM;
Clin Infect Dis; 2015 Sep; 61(6):883-91. PubMed ID: 26021992
[TBL] [Abstract][Full Text] [Related]
5. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
Boyd A; Gozlan J; Maylin S; Delaugerre C; Peytavin G; Girard PM; Zoulim F; Lacombe K
Hepatology; 2014 Aug; 60(2):497-507. PubMed ID: 24752996
[TBL] [Abstract][Full Text] [Related]
6. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
Boyd A; Bottero J; Miailhes P; Lascoux-Combe C; Rougier H; Girard PM; Serfaty L; Lacombe K
J Int AIDS Soc; 2017 Feb; 20(1):21426. PubMed ID: 28362068
[TBL] [Abstract][Full Text] [Related]
7. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.
Audsley J; Bent SJ; Littlejohn M; Avihingsanon A; Matthews G; Bowden S; Bayliss J; Luciani F; Yuen L; Fairley CK; Locarnini S; Lewin SR; Sasadeusz J
AIDS; 2016 Jun; 30(10):1597-606. PubMed ID: 26950313
[TBL] [Abstract][Full Text] [Related]
8. Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression.
Huang AJ; Núñez M
J Int Assoc Provid AIDS Care; 2015; 14(4):360-8. PubMed ID: 25999329
[TBL] [Abstract][Full Text] [Related]
9. Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study.
Dezanet LNC; Miailhes P; Lascoux-Combe C; Chas J; Maylin S; Gabassi A; Rougier H; Delaugerre C; Lacombe K; Boyd A
J Antimicrob Chemother; 2021 Oct; 76(11):3009-3019. PubMed ID: 34458919
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy.
Weissmann L; Picone CM; Gouvêa MSG; Ferreira PRA; Viana MSVB; Pinho JRR; Cassenote AJF; Segurado AC
Braz J Infect Dis; 2019; 23(6):441-450. PubMed ID: 31715124
[TBL] [Abstract][Full Text] [Related]
11. Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.
Boyd A; Gozlan J; Miailhes P; Lascoux-Combe C; Cam MS; Rougier H; Zoulim F; Girard PM; Lacombe K
AIDS; 2015 Sep; 29(15):1963-73. PubMed ID: 26153669
[TBL] [Abstract][Full Text] [Related]
12. Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia.
Vinikoor MJ; Sinkala E; Chilengi R; Mulenga LB; Chi BH; Zyambo Z; Hoffmann CJ; Saag MS; Davies MA; Egger M; Wandeler G;
Clin Infect Dis; 2017 May; 64(10):1343-1349. PubMed ID: 28158504
[TBL] [Abstract][Full Text] [Related]
13. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
Matthews GV; Seaberg EC; Avihingsanon A; Bowden S; Dore GJ; Lewin SR; Sasadeusz J; Revill PA; Littlejohn M; Hoy JF; Finlayson R; Ruxrungtham K; Saulynas M; Locarnini S; Thio CL
Clin Infect Dis; 2013 May; 56(9):e87-94. PubMed ID: 23315316
[TBL] [Abstract][Full Text] [Related]
14. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
Huang YS; Chang SY; Sheng WH; Sun HY; Lee KY; Chuang YC; Su YC; Liu WC; Hung CC; Chang SC
PLoS One; 2016; 11(12):e0169228. PubMed ID: 28033344
[TBL] [Abstract][Full Text] [Related]
15. Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?
Audsley J; Avihingsanon A; Littlejohn M; Bowden S; Matthews GV; Fairley CK; Lewin SR; Sasadeusz J
J Acquir Immune Defic Syndr; 2020 Aug; 84(5):527-533. PubMed ID: 32692112
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B viral replication markers and hepatic fibrosis in untreated chronic hepatitis B virus infection with and without HIV coinfection in Zambia.
Muula GK; Bosomprah S; Sinkala E; Nsokolo B; Musonda T; Hamusonde K; Bhattacharya D; Lauer G; Chung RT; Mulenga LB; Wandeler G; Vinikoor MJ
AIDS; 2023 Nov; 37(13):2015-2020. PubMed ID: 37467044
[TBL] [Abstract][Full Text] [Related]
17. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
Boyd A; Moh R; Gabillard D; le Carrou J; Danel C; Anglaret X; Eholié SP; Maylin S; Delaugerre C; Zoulim F; Girard PM; Lacombe K;
Antivir Ther; 2015; 20(6):643-54. PubMed ID: 25852125
[TBL] [Abstract][Full Text] [Related]
18. Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection.
Huang YS; Sun HY; Chang SY; Chuang YC; Cheng A; Huang SH; Huang YC; Chen GJ; Lin KY; Su YC; Liu WC; Hung CC
Hepatol Int; 2019 Jul; 13(4):431-439. PubMed ID: 31177505
[TBL] [Abstract][Full Text] [Related]
19. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
Lewin SR; Ribeiro RM; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini SA; Ruxrungtham K; Perelson AS; Dore GJ
Hepatology; 2009 Apr; 49(4):1113-21. PubMed ID: 19115219
[TBL] [Abstract][Full Text] [Related]
20. Correlation of serum hepatitis B core-related antigen with hepatitis B virus total intrahepatic DNA and covalently closed circular-DNA viral load in HIV-hepatitis B coinfection.
Dezanet LNC; Maylin S; Gabassi A; Rougier H; Miailhes P; Lascoux-Combe C; Chas J; Girard PM; Delaugerre C; Zoulim F; Lacombe K; Boyd A
AIDS; 2020 Nov; 34(13):1943-1949. PubMed ID: 32773480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
